First Author: S.Gonul TURKEY
Co Author(s): B.T. Ozturk B. Bakbak S. Okudan 0 0 0 0 0 0 0 0 0
Back to previous
To evaluate the effect of single intravitreal dexamethasone implant injection in eyes with persistent diabetic macular edema (DME).
Selcuk University Faculty of Medicine, Department of Ophthalmology, Konya, Turkey
Ten patients who received Ozurdex intravitreal implant injection due to persistent DME were evaluated retrospectively. Main outcome measures included changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT).
Ten eyes of 10 patients (4 females, 6 males; mean age 53 years) were included in the study. The mean duration of DME was 25.4 months (range 12–55 months). All patients had undergone previous treatments for DME including intravitreal injection of anti-vascular endothelial growth factor, steroids or laser photocoagulation). At baseline, the mean BCVA was 34 letters, and the mean CRT was 602±157.12 µm. BCVA improved to 43 letters at the first month visit and remained stable at the second and third months controls (p = 0.02). However, at the 5th month visit, it decreased again to 32 letters (p = 0.6). The mean CRT improved to 317±115.11 µm, 311±104.41 µm. and 325±125.18 µm (p = 0.04) at the first, second and third months of follow-up and increased again to 537±162.82 µm (p = 0.13) at 5 months. During the follow-up period only one eye developed a moderate intraocular pressure (IOP) rise 1 month after injection, which was necessitated topical IOP-lowering therapy.
This small group of patients with persistent DME demonstrates a promising improvement after Ozurdex intravitreal implant injection. Though it wears off after 3rd month, a 5 month period without injection may be an advantage in this group of patients.